| Literature DB >> 35456183 |
Sophie Urtado1, Hélène Hergault1,2, Stephen Binsse3, Vincent Aidan1, Mounir Ouadahi1, Catherine Szymanski1,2, Sophie Mallet1, Marie Hauguel-Moreau1,2, Robert Yves Carlier3,4, Olivier Dubourg1,2, Nicolas Mansencal1,2.
Abstract
BACKGROUND: We assessed the usefulness of a longitudinal strain adjusted to regional thickness in hypertrophic cardiomyopathy (HCM). Indeed, with conventional software, the width of the region of interest (ROI) is the same over the entire myocardial wall, wherein the software analyzes only partially the left ventricular (LV) hypertrophic segments.Entities:
Keywords: fibrosis; hypertrophic cardiomyopathy; strain
Year: 2022 PMID: 35456183 PMCID: PMC9024891 DOI: 10.3390/jcm11082089
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1Myocardial contouring in the same apical four-chamber view (A): with standard software and (B): with software adjusted to the myocardial wall thickness.
Clinical characteristics of HCM group and control group.
| HCM Group | Control Group | |
|---|---|---|
| Men, n (%) | 38 (69%) | 38 (69%) |
| Mean age, years | 47 ± 19 | 47 ± 19 |
| Previous history | ||
| Syncope, n (%) | 6 (11%) | 0 (0%) |
| Chest pain, n (%) | 4 (7%) | 0 (0%) |
| Family history of sudden cardiac death, n (%) | 6 (11%) | 0 (0%) |
| Supraventricular tachycardia, n (%): | 13 (24%) | 0 (0%) |
| Atrial fibrillation | 9 (16%) | 0 (0%) |
| Atrial flutter | 1 (2%) | 0 (0%) |
| Wolff–Parkinson–White syndrome | 2 (4%) | 0 (0%) |
| Dyspnea (NYHA classification) * | ||
| Class I, n (%) | 22 (56%) | 55 (100%) |
| Class II, n (%) | 18 (32%) | 0 (0%) |
| Class III, n (%) | 6 (11%) | 0 (0%) |
| Class IV, n (%) | 0 | 0 (0%) |
| Heart rate, /min | 68 ± 13 | 75 ± 11 |
| Systolic blood pressure, mmHg | 122 ± 20 | 125 ± 11 |
| Diastolic blood pressure, mmHg | 73 ± 10 | 74 ± 8 |
| NSVT on Holter ECG, n (%) | 5 (9%) | NA |
| Hypotensive blood pressure response to exercise, n (%) | 2 (4%) | NA |
| Identified gene mutation, n (%) | 23 (42%) | NA |
| Myosin-binding protein C (MYBPC3), n (%) | 15 (27%) | |
| Beta-myosin heavy chain (MYH7), n (%) | 6 (11%) | |
| Cardiac troponin T (TNNT2), n (%) | 1 (2%) | |
| Protein kinase A, gamma unit (PKRAG2), n (%) | 1 (2%) | |
| Significant myocardial fibrosis on CMR, n (%) | 17 (31%) | NA |
| Medication | ||
| Beta-blockers, n (%) | 37 (67%) | 0 (0%) |
| ACE inhibitor/ARA, n (%) | 3 (5%) | 0 (0%) |
| Diuretics, n (%) | 10 (18%) | 0 (0%) |
| Disopyramide, n (%) | 6 (11%) | 0 (0%) |
| Amiodarone, n (%) | 2 (4%) | 0 (0%) |
| Flecainide, n (%) | 2 (4%) | 0 (0%) |
| Dual-chamber pacemaker implantation/ICD, n (%) | 6 (11%) | 0 (0%) |
| Septal alcohol ablation, n (%) | 5 (9%) | - |
| Myoto myomectomy, n (%) | 2 (4%) | - |
| 5-year sudden cardiac death risk score, n (%) | 3.56 ± 7.06 | NA |
ACE inhibitor/ARA, angiotensin-converting enzyme inhibitor/angiotensin II receptor antagonist; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; CMR, cardiac magnetic resonance; NA, not applicable; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association. * p < 0.001 between HCM group and control group.
Echocardiographic characteristics of HCM and control groups.
| HCM Group | Control Group | |
|---|---|---|
| LV diastolic diameter (mm) * | 44.6 ± 5.9 | 48.7 ± 5.2 |
| Maximal septal thickness (mm) * | 19.1 ± 6.4 | 7.9 ± 1.5 |
| LV ejection fraction | 60 ± 11 | 62 ± 3 |
| Septum/posterior wall ratio * | 1.89 ± 0.73 | 1.05 ± 0.02 |
| Maron index (mm) | 56.8 ± 14.4 | NA |
| Systolic anterior motion, n (%) | 27 (49%) | 0 (0%) |
| Maximal left ventricular gradient | NA | |
| Mean values (mmHg) | 42 ± 20 | |
| Superior to 30 mmHg, n (%) | 16 (29%) | |
| Left atrial diameter (mm) * | 41.3 ± 7.8 | 35.4 ± 3.2 |
| Mitral regurgitation | ||
| Grade II or above, n (%) | 8 (14%) | 0 (0%) |
| Mitral regurgitation related to SAM, n (%) | 6 (11%) | 0 (0%) |
| HCM pattern (Maron classification) | NA | |
| Type 1, n (%) | 11 (20%) | |
| Type 2, n (%) | 5 (9%) | |
| Type 3, n (%) | 32 (58%) | |
| Type 4, n (%) | 7 (13) | |
| Apical HCM, n (%) | 5 (9%) | NA |
HCM, hypertrophic cardiomyopathy; LV, left ventricular; NA, not applicable; SAM, systolic anterior motion. * p < 0.001 between HCM group and control group.
Regional longitudinal strain with standard analysis and strain adjusted for thickness (mid-wall layer).
| Longitudinal Strain (%) | Standard | Adjusted | |
|---|---|---|---|
| Basal inferoseptal segment | −10.6 ± 6.8 | −8.6 ± 6.3 | 0.0002 |
| Median inferoseptal segment | −14.2 ± 6.5 | −12.3 ± 7.1 | 0.001 |
| Apical inferoseptal segment | −18.1 ± 7.4 | −21.4 ± 9.6 | 0.003 |
| Basal anterolateral segment | −13.8 ± 8.1 | −13.8 ± 6.2 | 0.94 |
| Median anterolateral segment | −13.0 ± 6.9 | −13.2 ± 7.4 | 0.78 |
| Apical anterolateral segment | −15.3 ± 7.2 | −18.6 ± 11.3 | 0.08 |
| Basal anteroseptal segment | −10.7 ± 7.8 | −8.4 ± 5.8 | 0.067 |
| Median anteroseptal segment | −13.7± 6.4 | −12.5 ± 6.7 | 0.02 |
| Apical segment | −16.9 ± 7.1 | −18.6 ± 8.4 | 0.005 |
Figure 2Bland–Altman plots of (A) basal inferoseptal (BIS) segment strain and (B) median inferoseptal segment strain for conventional and mid-wall adjusted ROI strains. Dashed lines, 1.96 SDs from the mean. BIS: basal inferoseptal, MIS: median inferoseptal, ROI: region of interest.